- Home
- SCD vs AVIR Comparison
SCD vs AVIR Comparison
Compare SCD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- AVIR
- Stock Information
- Founded
- SCD 2003
- AVIR 2012
- Country
- SCD United States
- AVIR United States
- Employees
- SCD N/A
- AVIR N/A
- Industry
- SCD Trusts Except Educational Religious and Charitable
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- SCD Finance
- AVIR Health Care
- Exchange
- SCD Nasdaq
- AVIR Nasdaq
- Market Cap
- SCD 264.7M
- AVIR 290.4M
- IPO Year
- SCD N/A
- AVIR 2020
- Fundamental
- Price
- SCD $15.68
- AVIR $2.99
- Analyst Decision
- SCD
- AVIR Hold
- Analyst Count
- SCD 0
- AVIR 1
- Target Price
- SCD N/A
- AVIR $6.00
- AVG Volume (30 Days)
- SCD 62.6K
- AVIR 342.6K
- Earning Date
- SCD 01-01-0001
- AVIR 11-06-2025
- Dividend Yield
- SCD 9.63%
- AVIR N/A
- EPS Growth
- SCD N/A
- AVIR N/A
- EPS
- SCD N/A
- AVIR N/A
- Revenue
- SCD N/A
- AVIR N/A
- Revenue This Year
- SCD N/A
- AVIR N/A
- Revenue Next Year
- SCD N/A
- AVIR N/A
- P/E Ratio
- SCD N/A
- AVIR N/A
- Revenue Growth
- SCD N/A
- AVIR N/A
- 52 Week Low
- SCD $11.33
- AVIR $2.46
- 52 Week High
- SCD $15.87
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- SCD 57.15
- AVIR 44.40
- Support Level
- SCD $15.42
- AVIR $2.78
- Resistance Level
- SCD $15.62
- AVIR $2.94
- Average True Range (ATR)
- SCD 0.16
- AVIR 0.11
- MACD
- SCD -0.01
- AVIR 0.02
- Stochastic Oscillator
- SCD 52.83
- AVIR 78.18
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).